Home/NeoGenomics/Lynn A. Tetrault
LA

Lynn A. Tetrault

Chair of the Board

NeoGenomics

Therapeutic Areas

NeoGenomics Pipeline

DrugIndicationPhase
RaDaR® STMinimal Residual Disease (MRD) detection and recurrence monitoring across solid tumorsCommercial
NEO | PanTracer™ ProComprehensive genomic profiling for personalized therapy selection in oncologyCommercial
Portfolio of >500 TestsVarious solid tumors and hematologic cancers (e.g., lung, breast, leukemia)Commercial